Oncotarget

Corrections:

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

PDF  |  How to cite

Oncotarget. 2018; 9:36048-36048. https://doi.org/10.18632/oncotarget.26373

Metrics: PDF 545 views  |   ?  

Toril Holien1, Kristine Misund1, Oddrun Elise Olsen1, Katarzyna Anna Baranowska1, Glenn Buene1, Magne Børset1,2, Anders Waage1,3 and Anders Sundan1,4

1 K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
2 Department of Immunology and Transfusion Medicine, St. Olav’s University Hospital, Trondheim, Norway
3 Department of Hematology, St. Olav’s University Hospital, Trondheim, Norway
4 CEMIR (Centre of Molecular Inflammation Research), Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Published: November 13, 2018

This article has been corrected: The legends for figures 1 and 2 were accidentally switched. The corrected figure legends are given below:

Figure 1: Expression of MYC in myeloma cell lines correlated positively with sensitivity to MYC inhibition. The IC50- values of the MYC inhibitor 10058-F4 calculated from the results shown in Supplementary Figure 2 was compared with A. MYC mRNA values or B. MYC/GAPDH relative protein levels. The slope and R2-values are shown in the plots.

Figure 2: MYC gene copy numbers determine expression of MYC mRNA and protein in myeloma cell lines. In a panel of myeloma cell lines the levels of MYC gene copy numbers as measured by PCR was related to A. MYC mRNA measured using nCounter, and B. MYC protein levels measured using immunoblotting and normalized to GAPDH. The slope and R2-values are shown in the plots.

Original article: Oncotarget. 2015; 6:22698-22705. DOI: https://doi.org/10.18632/oncotarget.4245.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26373